Cell Type-Specific Modulation of Respiratory Chain Supercomplex Organization

Dayan Sun †, Bin Li †, Ruyi Qiu, Hezhi Fang * and Jianxin Lyu *

Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China; dayansun0128@163.com (D.S.); zblibin123@163.com (B.L.); 15167797018@163.com (R.Q.)

* Correspondence: FangH@WMU.edu.cn (H.F.); ljx@wmu.edu.cn (J.L.); Tel.: +86-577-8668-9805 (H.F. & J.L.)

† These authors contributed equally to this work.

Abstract: Respiratory chain complexes are organized into large supercomplexes among which supercomplex In + IIIn + IVn is the only one that can directly transfer electrons from NADH to oxygen. Recently, it was reported that the formation of supercomplex In + IIIn + IVn in mice largely depends on their genetic background. However, in this study, we showed that the composition of supercomplex In + IIIn + IVn is well conserved in various mouse and human cell lines. Strikingly, we found that a minimal supercomplex In + IIIn, termed “lowest supercomplex” (LSC) in this study because of its migration at the lowest position close to complex V dimers in blue native polyacrylamide gel electrophoresis, was associated with complex IV to form a supercomplex In + IIIn + IVn in some, but not all of the human and mouse cells. In addition, we observed that the 3697G>A mutation in mitochondrial-encoded NADH dehydrogenase 1 (ND1) in one patient with Leigh’s disease specifically affected the assembly of supercomplex In + IIIn + IVn containing LSC, leading to decreased cellular respiration and ATP generation. In conclusion, we showed the existence of LSC In + IIIn + IVn and impairment of this supercomplex causes disease.

Keywords: mitochondrial supercomplex; nuclear genetic background; respiratory chain; mitochondrial dysfunction; Leigh’s disease

1. Introduction

Mitochondria are the power plants of the cell, generating Adenosine triphosphate (ATP) through the oxidative phosphorylation (OXPHOS) system. In mammals, the OXPHOS system consists of five complexes (I to V) that are embedded in the inner mitochondrial membrane and harbor two mobile electron carriers, ubiquinone and cytochrome c (cyt c). In the electron transfer chain (ETC), electrons are transferred among these complexes generating a proton gradient across the inner mitochondrial membrane, which is used by complex V (F1F0-ATP synthase) to synthesize ATP from ADP [1]. Electrons from complexes I (NADH dehydrogenase) and II (succinate dehydrogenase) are transferred to complex III (coenzyme Q-cyt c reductase) via ubiquinone. Finally, complex IV (cyt c oxidase) receives electrons from complex III via cyt c to reduce molecular oxygen to water.

Historically, respiratory chain complexes have been thought to randomly diffuse throughout the inner mitochondrial membrane [2]. In the “fluid state model”, electron transfer is based on random collision of the electron carriers within the respiratory complexes. However, this model challenged the old “solid state model”, in which the respiratory complexes have been suggested to be organized into bigger super molecules [3]. In 2000, Hermann Schägger and Kathy Pfeiffer proposed the concept of “supercomplexes” or “respirasomes” after they observed the existence of In + IIIn + IVn super
molecules by blue native polyacrylamide gel electrophoresis (BN-PAGE) [4]. Currently, an intermediate model put forward by Acin-Perez et al. (2008) in which both freely moving OXPHOS complexes (fluid state model) and supercomplexes (solid state model) co-exist in the mitochondrial membrane, is generally accepted [5,6]. It has been hypothesized that the occurrence of supercomplexes stabilizes the structure of single complexes [7–9] and facilitates faster and more efficient electron transfer, while limiting the generation of reactive oxygen species (ROS) [10]. However, recent evidence suggests that supercomplexes are not kinetically important for substrate channeling [11]. Thus, the role of supercomplexes in respiration remains to be fully elucidated.

BN-PAGE is a powerful technique for the analysis of respiratory chain supercomplexes, that allowed the isolation and characterization of the respiratory chain complexes from yeast (Saccharomycetes cerevisiae) and mammalian mitochondria [4,12]. Over the last years, the organization of supercomplexes in mammalian mitochondria has been extensively documented in animal models including mouse cell lines and bovine heart tissues using structural biology methods and BN-PAGE [5,13,14]. However, the association of single complexes within the supercomplexes in mammals remains controversial. Lapuente-Brun et al. reported that the assembly of supercomplexes differs in mouse strains with different genetic backgrounds such as C57BL/6J, BALB/c, and 129Sv [15], and that C57BL/6J mice do not have supercomplexes In + IIIn + IVn and III2 + IV. In 2014, this finding was challenged by Mourier et al. who showed that C57BL/6J, BALB/c, and CD1 mouse cells all possess well-organized supercomplex In + IIIn + IVn [16], but not III2 + IV.

The organization of individual respiratory chain complexes into supercomplexes has major implications for human diseases; remodeling of the supercomplexes plays a key role in cancer-related metabolic reprogramming [17] and ROS production associated with aging [6], as well as in mitochondrial dysfunction-associated heart failure [18]. However, the composition of human respiratory chain supercomplexes has not been elucidated yet. In this study, we examined the components of respiratory chain supercomplexes in humans and mice by using multiple human and mouse cell lines.

2. Results

2.1. Respiratory Chain Supercomplexes in Humans and Mice

To clarify whether the nuclear genetic background affects the formation and composition of supercomplexes, we investigated supercomplex organization in various human and mouse cell lines by standard BN-PAGE and subsequent immunoblotting. We found that cybrid 3A19 cells with the C57BL nuclear genetic background contain both IIIn + IVn and In + IIIn + IVn supercomplexes (Figure 1A). We further confirmed that C57BL/6J mice with short form of cyt c oxidase subunit 7a polypeptide 2-like gene (COX7a2l) contain both IIIn + IVn and In + IIIn + IVn supercomplexes (Figure S1A,B). Western blot analysis of mitochondrial proteins of HIB1B, A9, 3T3-L1, and C2C12 cells from Swiss Webster, C3H/An, Swiss albino, and C3H mouse strains, respectively, revealed the presence of complex IV-containing IIIn + IVn and In + IIIn + IVn supercomplexes in the different cell types (Figure 1B–E and Table S1). Similarly, complex IV-containing supercomplexes were detected in HeLa, MDA-MB-231, and 143B human cells (Figure 1F–H).

Currently, it is generally accepted that respiratory chain supercomplexes with molecular weights greater than that of complex V dimers correspond to In + IIIn and In + IIIn + IVn. Figure S1A clearly indicates that the lowest supercomplex (LSC) is composed of In + IIIn in C57BL/6J mice, while complex IV was not detected. Interestingly, we found that the 3T3-L1 and C2C12 mouse cells (Figure 1D,E) and MDA-MB-231 and 143B human cells (Figure 1G,H) did not have In + IIIn at the LSC position. Instead, In + IIIn + IVn was detected in these cell lines. To exclude potential artifacts associated with the use of detergents, we confirmed the existence of the LSC In + IIIn + IVn in C2C12 and 143B cells treated with different digitonin/protein ratios of 4, 6, and 8 g/g (Figure S1C,D). Additionally, 143B cells with different mtDNA backgrounds—B4, D4, and F2—showed the same pattern of supercomplexes, and the
composition of the LSC was In + IIIIn + IVn in all cell lines, indicating that the mtDNA background itself does not affect the supercomplex organization (Figure S1E).

Figure 1. Respiratory chain supercomplexes in human and mouse cell lines. (A–H) BN-PAGE and western blot analysis of mitochondrial lysates from digitonin-solubilized 3A19 (A), HIB1B (B), A9 (C), 3T3-L1 (D), C2C12 (E), HeLa (F), MDA-MB-231 (G), and 143B (H) cells. The blots were probed with anti-Grim19, anti-Core2, and anti-COX IV; (I) BN-PAGE and Western blot analysis of individual OXPHOS complexes prepared with DDM. Blots for samples from control (left) and patient 3 (right) were probed with anti-Grim19; (J) BN-PAGE and Western blot analysis of digitonin-treated mitochondrial protein. Blots for samples from control (left) and patient 3 (right) were probed with anti-Grim19, anti-Core2, and anti-COXIV; (K) SDS-PAGE and Western blot/analysis of the LSC band excised from the gel after BN-PAGE. Blots were probed with anti-Grim19, anti-Core2, and anti-COX1, and anti-cyt c, respectively. In (A–K): n = 3. CI: complex I; CIII: complex III; CIV: complex IV.

In HeLa cells and mouse 3A19, HIB1B, and A9 cells, In + IIIIn was detected at the LSC position (Figure 1A–C). Using 2D BN/SDS-PAGE, we confirmed that complex IV was associated with In + IIIIn at the LSC position in protein lysates from 143B cells when compared to those from HIB1B cells (Figure S2A,B). Notably, although both the A9 and C2C12 cell lines originate from the mouse strain C3H, they exhibited a different LSC composition (Table S1). In addition, A9 and C2C12 cells displayed numerical chromosome variations; A9 was found to be aneuploid, while C2C12 was euploid [19,20]. Similarly, the nuclear genetic backgrounds of HIB1B and 3T3-L1 were different as they originated from outbred and inbred Swiss mouse strains, respectively [21,22]. To test whether culture conditions can affect the LSC organization, we cultured 143B and HeLa cells in medium containing 10 mM galactose instead of...
glucose. As shown in Figure S1F,G, the composition of the LSCs in both 143B and HeLa cells was not affected. Furthermore, co-migration of the LSCs from HeLa (In + IIIn) and 143B cells (In + IIIn + IVn) were detected by separating the mitochondrial complexes through BN-PAGE in the same gel. Taken together, these results suggested that the organization of supercomplex associated are cell type specific.

To investigate whether the In + IIIn + IVn supercomplex is present in different cell types, lymphoblastoid cell lines from three healthy subjects were immortalized. As shown in Figure S3, BN-PAGE showed the co-migration of complexes I, III, and IV. Strikingly, most In + IIIn + IVn was found at the LSC position in the immortalized lymphoblastoid cell lines. Therefore, we speculated that the LSC composed of In + IIIn + IVn is functionally important in mitochondria. Notably, in the lymphoblastoid cell line from patient 3, with a 595C>T mutation in the Nicotinamide adenine dinucleotide (NADH) dehydrogenase [ubiquinone] iron-sulfur protein 3 gene (NDUFS3; R199W transition at protein level), a defect of complex I impaired the assembly of complexes I, III, and IV at the LSC position as compared to those of control cells (Figure 1I,J), indicating the existence of the In + IIIn + IVn LSC. It was reported that the ratio of complex I/complex III in In + IIIn LSC was 1:2 [5]. While the molecular weights of In + IIIn LSC and In + IIIn + IVn LSC are similar, it is more likely that the ratio of complex I/complex III/complex IV in In + IIIn + IVn LSC is 1:1:1.

Cyt c has been demonstrated to co-migrate with supercomplex In + IIIn + IVn [5,23]. To determine whether the In + IIIn + IVn LSC contains cyt c, LSC proteins were excised from the BN gel and were separated with a second-dimension SDS-PAGE. As shown in Figure 1K, the LSCs of both 143B and HeLa cells contained complexes I and III. Complex IV was found in 143B cells; however, it was barely detected in HeLa cells (Figure 1K). In addition, cyt c was found only in the LSC of 143B cells.

2.2. Dynamics of Respiratory Chain LSC

The dynamics of respiratory chain supercomplexes, in which an 830-kDa complex I intermediate constitutes the supercomplex assembly intermediate, have been previously described [24]. After the addition of complexes III and IV, the NADH dehydrogenase module of complex I is incorporated to finish supercomplex assembly. In this model, single complex I without NADH dehydrogenase never gets fully assembled and activated when it binds to other respiratory chain complexes. These findings indicated the significance of the supercomplexes for respiratory chain function, and that altered LSC dynamics can probably affect mitochondrial function.

To determine the assembly of the different complexes within the LSCs, we depleted the respiratory complexes and supercomplexes in HIB1B and C2C12 cells by treating them with chloramphenicol (CAP), which reversibly inhibits mitochondrial translation but does not affect mtDNA copy number (Figure S4). The cells were co-cultured with CAP for 4–5 days to exhaust pre-existing respiratory chain complexes, and then, the synthesis of mtDNA-encoded OXPHOS subunits and their incorporation into respiratory chain complexes were monitored after drug removal. We observed that the assembly of the LSC in both the HIB1B (In + IIIn) and C2C12 (In + IIIn + IVn) cells started as early as 4 h after drug removal (Figure 2A,B). HIB1B cells showed an approximately 32-fold increase in LSC content between 4 and 48 h after drug removal. In contrast, in C2C12 cells, a 25-fold increase in LSC content was observed during this period. The lower prevalence of LSC assembly in C2C12 cells at 48 h in C2C12 cells was confirmed by monitoring complex III-containing LSC assembly in both C2C12 and HIB1B cells (Figure S5A,B). The results corroborated that the assembly of complex IV-containing LSC was slower than that of LSC without complex IV.

Monitoring of the disassembly of the respiratory chain complexes during CAP treatment showed that disassembled LSC in HIB1B cells was 71.18% of total LSC after 24-h treatment with CAP (Figure 2C). In C2C12 cells, the disassembled portion (36.07%) was substantially lower than that in HIB1B cells (Figure 2D). We confirmed that the disassembled portion of LSC in C2C12 cells was lower than that in HIB1B cells by tracing the complex III-containing LSC (Figure S5C,D). Taken together, these observations indicated that LSCs containing IVn are more stable than those without complex IV.
which changes a highly conserved glycine to serine at the 131st residue in MT-ND1, was observed in patient 1 (total number of reads: 3322; G = 0; A = 3322), while it was not detected in blood from the patient’s mother (Figure S7). To examine the pathogenic function of this mutation, we generated cybrid cells with different m.3697G>A mutation loads. Based on the results of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, “L” and “H” cells with mutation loads of 0% and 96%, respectively, were selected for further analysis (Figure S8). Acquisition of private mtDNA mutations during cybrid selection in these two cell lines was excluded by whole mitochondrial genome sequencing (Table S2).

Next, we evaluated whether the m.3697G>A mutation led to impaired assembly of complex I. Total mitochondrial protein isolated from L and H cells was separated by BN-PAGE for immunoblot analysis of complex I with antibody against MT-ND1 or NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 13 (NDUFA13, also termed Grim19). As shown in Figure 3A,B, H cells contained less intact complex I than L cells. However, the assembly of complexes II, III, IV, and V did not differ between L and H cells (Figure 3B). In addition, the subunit peptides of complexes I, II, III, IV, and V were not different between both cell lines (Figure S9). Since a previous study showed that most of the 3697G>A mutation is not fully known. In line with a previous report [26], the mutation was found in the homoplasmic state in blood from patient 1 (Figure S6). This mutation was first identified in a patient with mitochondrial encephalopathy, lactic acidosis, and a stroke-like episode (MELAS) in 2004 [25] and was later reported in a patient with Leigh’s disease [26]; however, the pathogenic effect of the m.3697G>A mutation is not fully known.

2.3. Mitochondrial NADH Dehydrogenase Subunit 1 (MT-ND1) 3697G>A Mutation Impairs LSC Formation

To provide initial evidence that the LSC plays a role in mitochondrial biogenesis, we conducted BN-PAGE analysis of samples from patients with OXPHOS defects. The 3697G>A mutation in MT-ND1, which changes a highly conserved glycine to serine at the 131st residue in MT-ND1, was observed in patient 1 (Figure S6). This mutation was first identified in a patient with mitochondrial encephalopathy, lactic acidosis, and a stroke-like episode (MELAS) in 2004 [25] and was later reported in a patient with Leigh’s disease [26]; however, the pathogenic effect of the m.3697G>A mutation is not fully known. In line with a previous report [26], the mutation was found in the homoplasmic state in blood from patient 1 (total number of reads: 3322; G = 0; A = 3322), while it was not detected in blood from the patient’s mother (Figure S7). To examine the pathogenic function of the mutation, we generated cybrid cells with different m.3697G>A mutation loads. Based on the results of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, “L” and “H” cells with mutation loads of 0% and 96%, respectively, were selected for further analysis (Figure S8). Acquisition of private mtDNA mutations during cybrid selection in these two cell lines was excluded by whole mitochondrial genome sequencing (Table S2).

Next, we evaluated whether the m.3697G>A mutation led to impaired assembly of complex I. Total mitochondrial protein isolated from L and H cells was separated by BN-PAGE for immunoblot analysis of complex I with antibody against MT-ND1 or NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 13 (NDUFA13, also termed Grim19). As shown in Figure 3A,B, H cells contained less intact complex I than L cells. However, the assembly of complexes II, III, IV, and V did not differ between L...
and H cells (Figure 3B). In addition, the subunit peptides of complexes I, II, III, IV, and V were not different between both cell lines (Figure S9). Since a previous study showed that most of complex I (86%) was incorporated into supercomplexes [27], we checked whether the m.3697G>A mutation impaired mitochondrial function through aberrant supercomplex formation. We determined the I-, III-, and IV-containing supercomplexes by BN-PAGE analysis of digitonin-solubilized mitochondrial samples. Interestingly, the amount of In + III + IVn LSC was significantly decreased in H cells as compared to L cells, while the amount of other supercomplexes was not affected (Figure 3C).

The monomeric form of complex I was hardly detected in both L and H cells (Figure 3C). By using 2D BN/SDS-PAGE, we confirmed that the abundance of In + III + IVn LSCs was much higher in L than in H cells (Figure 3D). Analysis of the LSC dynamics using CAP treatment of the cells showed faster LSC assembly in L than in H cells between 0 and 48 h after CAP removal (Figure 3E). In two cybrids derived from family of patient 2 with Leigh’s disease and harboring m.14487T>C mutation loads of 11% and 96%, we did not find any alterations in the LSC from the patient (Figure S10). Taken together, our observations demonstrated that specific mutations such as m.3697G>A can affect the assembly of the LSC, which may result in impaired function of OXPHOS. However, the effect of m.3697G>A on the formation of In + III + IVn LSCs is not known.

![Figure 3](image-url)  
**Figure 3.** The m.3697G>A mutation impaired respiratory chain LSC. (A) Mitochondria from clones L and H were treated with N-dodecyl-β-D-maltoside (DDM) to solubilize individual OXPHOS complexes. In-gel activity assay of complex I was performed after BN-PAGE. Blots of mitochondrial protein prepared with DDM from clones L and H were probed with anti-ND1 antibody; (B) Total mitochondrial protein from clones L and H were solubilized with DDM (2.5 g/g protein) and subjected to BN-PAGE and Western blot analysis. The blots were probed with anti-Grim19, anti-SDHA, anti-Core2, anti-COX IV, and anti-ATP5A, respectively; (C) Total mitochondrial protein from clones L and H was solubilized with digitonin (6 g/g protein) and subjected to BN-PAGE and immunoblot analysis. Blots were probed with anti-Grim19, anti-Core2, and anti-COX IV, respectively; (D) Total mitochondrial protein from clones L and H was solubilized with digitonin and subjected to 2D BN/SDS-PAGE and Western blotting. The blots were probed with anti-Grim19, anti-SDHA, anti-Core2, and anti-COX IV, respectively. Succinate dehydrogenase complex, subunit A (SDHA) was used as a loading control; (E) L and H cells were treated with chloramphenicol (CAP) for three days, followed by culture without CAP for 48 h. BN-PAGE and Western blot analysis of whole-cell lysates from digitonin-treated cells. The blots were probed with anti-Grim19. In (A–C), data are presented as the mean ± SD of three replicates; in (D): n = 2; because of large SDs, results in (E) are representative of three independent experiments. * p < 0.05.
The MT-ND1 3697G>A Mutation Induces OXPHOS Defect

m.3697G>A has been linked to Leigh syndrome in a few studies [26,28]. However, how m.3697G>A impairs OXPHOS function is unknown. To evaluate the mitochondrial function in cells with impaired LSC, endogenous mitochondrial respiration was measured in L and H cells. As shown in Figure 4A, although no significant decrease in base respiration was detected in intact cells, H cells showed a trend towards decreased respiration function. Further, OXPHOS-driven mitochondrial respiration was determined in L and H cells in the presence of oligomycin, which completely blocks the proton channel of ATPase. L cells exhibited higher coupled OXPHOS respiration, and consequently, higher mitochondrial membrane potential (MMP) than H cells (Figure 4A,B). These observations suggested that the m.3697G>A mutation in ND1 impairs mitochondrial function by decreasing the respiration ability of the electron transport chain.

**Figure 4.** m.3697G>A mutation-induced OXPHOS defect. (A) Changes in mitochondrial respiratory capacity were determined in clones L and H (n ≥ 3). Oligomycin (2.5 µg/mL) was used to measure OXPHOS-driven mitochondrial respiration, which was calculated by subtracting the uncoupled component from basal endogenous respiration; (B) MMP was determined in clones L and H. MMP levels were measured in cells treated with 30 nM tetramethylrhodamine (TMRM) for 20 min (n ≥ 4); (C) Total ATP content was measured in clones L and H. Rotenone-resistant ATP content was determined in cells treated with 200 nM rotenone for 24 h. Rotenone-sensitive ATP content was calculated by subtracting the rotenone-resistant component from the total ATP content (n ≥ 4); (D) Extracellular lactate levels of clones L and H were measured in the medium after 48 h in culture (n ≥ 4); (E) Mitochondrial ROS levels were determined in clones L and H. Complex I- and complex III-related ROS generation were measured upon inhibition with 1 µM rotenone for 1 h (n ≥ 4) and 5 µM antimycin A for 30 min (n ≥ 4), respectively. The levels of MMP, ATP, lactate, and ROS were normalized against total protein concentration. For (A), 3–4 technical replicates were included; Error bars, ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001.

To examine the effect of the m.3697G>A mutation on mitochondrial function further, ATP synthesis in the cells was determined. As shown in Figure 4C, although total ATP production in H cells was higher than that in L cells, ATP generation through respiratory complex I was lower in H than in L cells. Consequently, lactic acid generation was increased in the H cells due the shift of ATP generation from OXPHOS to glycolysis (Figure 4C,D). Furthermore, mitochondrial ROS production was significantly higher in the H than in the L cells (Figure 4E). After 1-h treatment with the complex I-related ROS-inducer rotenone, ROS were induced to comparable levels in both cell lines (Figure 4E). However, in L and H cells treated with the complex III-related ROS inducer Antimycin A, the total ROS
level increased in both L and H cells, remaining higher in the H cells than in the L cells. This indicated that the high ROS level in the H cells was caused by impairment of complex I.

3. Discussion

In this study, we demonstrated that different cell types from human subjects and various mouse strains possess the respiratory chain supercomplexes I + III + IV and I + III + IV. However, the composition of the LSC was variable in different cell types. We found that the I + III + IV LSC is functionally important in various human and mouse cells, which is in contradiction with previous reports that I + III is the only possible conformation of the LSC. The biological importance of the I + III + IV LSC was confirmed in different human mitochondrial disease models.

By BN-PAGE, some of the complexes in the OXPHOS system have been found to be organized into super molecular structures [4,12]. The existence of two major supercomplexes, I + III + IV, and I + III + IV, has been widely described [5,6,15,16,29]. Further, I + III + IV is the only supercomplex with the ability to respire [5]. Although I + III cannot respire, it was proposed to serve as an essential assembly intermediate of supercomplex I + III + IV [6]. Our observation that LSC assembly of I + III in HIB1B cells was faster than that of I + III + IV in C2C12 cells confirms the idea that I + III + IV is assembled by the addition of complex IV onto I + III.

A few supercomplex assembly factors (SCAFs) for I + III + IV have been identified [15,29–31]. Among these, respiratory supercomplex factors 1 and 2 (Rcf1/2) are not considered real SCAFs because depletion of III+IV in Rcf1/2-null yeast mutants was caused by impaired complex IV assembly [6]. Therefore, the human cytochrome oxidase subunit 7A-related protein (COX7RP (COX7a2l in mice)) may be the only true SCAF identified until date [15,29]. After the first description of COX7RP by Ikeda et al., Lapuente-Brun et al. found that various mouse strains including C57BL/6j, BALB/c, and 129sv had different isoforms of COX7a2l [15,29]. Consistent with the findings of Ikeda et al., Lapuente-Brun et al. showed that C57BL/6j and BALB/c mice with a short form of COX7a21 are not able to generate I + III + IV and III + IV supercomplexes, suggesting variable supercomplex organization in mice with different genetic backgrounds. We found that I + III + IV structure and activity were conserved in a cell line and liver tissue from C57BL/6j mice. Our results were in partial agreement with those from a recent study, in which supercomplex I + III + IV was found in C57BL/6j mouse, and its assembly seemed to be independent of COX7a2l [16]. However, our results do not exclude a role for COX7a21 in I + III + IV assembly as previously reported [15,16]. Both of these studies were focused on the long and short forms of COX7a2l, but in none of them the effect of replacing one form with the other on assembly of I + III + IV was checked [15,16,29]. We hypothesize that both long and short forms of the protein may be functionally important in the assembly of the supercomplex. Future research is needed to examine the impact of COX7a21 on supercomplex assembly at the mechanistic level.

Based on their findings, Lapuente-Brun et al. warned for potential serious implications for studies of metabolic processes due to defects in respiratory chain activity in some laboratory mouse strains. Therefore, in this study, we conducted BN-PAGE and Western blot analysis using cell lines from multiple commonly used mouse strains. Together with previous studies [15,16], we suggested that all common mouse strains including BALB/c, CBA, CD1, 129, C3H, C57BL/6j, and inbred and outbred Swiss mice contain supercomplex I + III + IV.

Supercomplex I + III is another major supercomplex in mammalian cells. Currently, the structure of I + III is well characterized; however, little is known about its biological function [11,32]. Although the structure and occurrence of this supercomplex have been confirmed in multiple species such as *Arabidopsis thaliana*, *Zea mays*, and *Bos taurus* [14,33,34], we found that I + III LSC occurs in some, but not all cell lines derived from various mouse strains and human subjects. Cells without I + III were found to contain I + III + IV as the LSC. The occurrence of supercomplex I + III + IV in the LSC in 143B cells was first reported by Moreno-Lastres et al. [24]. In their work, complex IV-containing supercomplexes in wild-type 143B cells co-localized with complex I and complex III at the LSC position, while mutant 143B cells lacking complex IV did not contain the fully
assembled LSC but accumulated supercomplex In + IIIIn. In line with these findings, this study showed an interaction between complex IV and In + IIIIn at the LSC position in 143B cells. Furthermore, the number of complex III structures in LSC with complex IV is probably lower than that in LSC without complex IV, while disruption of complex IV-containing LSC generates a supercomplex In + IIIIn with a molecular mass lower than of the LSC. In addition, complexome profiling has shown co-migration of complex I, III, and IV subunits at the 1456-kDa position in human embryonic kidney (HEK293) cells, indicating the occurrence of In + IIIIn + IVn rather than In + IIIIn at the LSC position (~1500 kDa) [34,35].

Recently, Lapuente-Brun et al. proposed a model in which complex In + IIIIn can either transfer electrons from NADH to freely embedded complex IV or act as an intermediate for further assembly into the In + IIIIn + IVn supercomplex [5,15]. However, Moreno-Lastres et al. suggested that supercomplex assembly is completed only after interaction between partially assembled complex I and multiple subunits from complexes I, III, and IV [24]. In the study of Lapuente-Brun et al., an A9 fibroblast cell line from an aneuploid C3H mouse strain was used, while Moreno-Lastres et al. used (Caucasian) human 143B cells. Interestingly, A9 and 143B cells were found to have In + IIIIn and In + IIIIn + IVn supercomplexes at the position of the LSC, respectively, suggesting that 143B cells may not have intermediate complex In + IIIIn for further assembly of In + IIIIn + IVn like A9 cells do. The use of different cells may partially explain the discrepancy between both models [5,24].

In conclusion, we investigated the possible contribution of the LSC In + IIIIn + IVn to mitochondrial function. We identified a homoplasmic m.3697G>A mutation in the MT-ND1 gene in a patient with Leigh’s disease, which coincided with decreased LSC In + IIIIn + IVn steady-state levels. Without affecting the formation of other supercomplexes, the m.3697G>A mutation, which is known to be associated with Leigh’s disease, induced decreased mitochondrial respiration and ATP production, as well as increased ROS and lactate levels. This is, to our knowledge, the first report describing the mechanism of m.3697G>A in mitochondrial disease, although the mutation in mitochondrial disease has been reported in several studies [26,28,36]. Given the functional importance of the LSC In + IIIIn + IVn, in addition to our findings that the composition of the LSC is variable in different cell types, we propose that mitochondria lacking In + IIIIn + IVn LSC contribute to the metabolic shift in different cell models. Although for reasons other than those put forward by Lapuente-Brun et al. [15], we suggest that caution should indeed be applied when using different mouse strains for metabolic studies, as differences in the composition of the LSC may have an impact on the results.

4. Materials and Methods

4.1. Characterization of Patients

Patient 1 (female, aged 9 years at the time of this report) was born into a non-consanguineous Chinese family and presented with clinical manifestation of Leigh’s disease. mtDNA analysis using next generation sequencing identified a homoplasmic m.3697G>A (p.G131S) mutation in mitochondrial ND1 gene.

Patient 2 (male, aged 4 years at the time of this report) was born into a non-consanguineous Chinese family and presented with clinical manifestation of Leigh’s disease. mtDNA analysis by Sanger sequencing identified a heteroplasmic (by 70%) m.14487T>C (p.M63V) mutation in mitochondrial ND6 gene.

Patient 3 (male, had died at 20 months at the time of this report) was born into a non-consanguineous Chinese family and presented with clinical manifestation of Leigh’s disease. Mutation analysis by whole exome sequencing identified a c.595C>T (p.R199W) mutation in the NDUFS3 gene (MIM 60384).

Informed consent was obtained from all subjects under protocols approved by the Ethical Committee of the Peking University First Hospital (May 2014).
4.2. Generation of Cell Lines and Culture Conditions

Transmitochondrial cybrids were obtained by fusion of mtDNA-less ρ0 human osteosarcoma 143B cells with platelets as described previously [37]. The transformant cybrid clones were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Waltham, MA, USA) containing 10% cosmic calf serum (Gibco, Carlsbad, CA, USA).

4.3. DNA Analysis

For patients 1 and 2, genomic DNA were extracted by following a SDS lysis protocol as described previously [38]. The entire mtDNA genome was Sanger sequenced on using 24 previously reported pairs of mtDNA primers [39]. For patient 3, whole exome sequencing was performed using Illumina Hiseq 2000 (100 bp-paired end reads).

Mutation loads of m.3697G>A in transmitochondrial cybrids were assessed by analysis of PCR-RFLP. The sequences of the primers used in this study were as follows: forward, 5’-TACTTCAC AAAGCCCTTCC-3’; reverse, 5’-ATGAAGAATAGGGCAAGGG-3’. PCR products were subjected to complete digestion with HhaI (Thermo Scientific, Waltham, MA, USA) at 37 °C. Quantification of the intensity of the bands was done by Gel-Pro Analyzer 4.0 (MediaCybernetics, Warrendale, PA, USA). Mutation loads for m.14487T>C were assessed using an allele specific amplification based real-time PCR method as described previously [40]. The sequences of the primers used in this study were as follows: mtDNA 14487T: forward, 5’-AGTATATCCCAAAGACAACCATC-3’; mtDNA 14487C: forward, 5’-AGTATATCCCAAAGACAACCATC-3’; reverse primer for mtDNA 14487T and mtDNA 14487C, 5’-TAATGGGGTTTGTGGGGTTT-3’.

4.4. mtDNA Copy Number Quantification

Genomic DNA was extracted using a SDS lysis protocol as described [38]. A ratio of mtDNA versus nDNA was generated to represent the relative amount of mtDNA copy number. The Real-Time PCR reactions were performed on a 7900HT Real-Time PCR system (Applied Biosystems, Waltham, MA, USA) using SYBR® Green qPCR Mastermix (Takara, Dalian, China). The detailed mouse primers were listed below: mtDNA ND2: forward, 5’-CCTATCACCCTTGCCATCAT-3’; reverse, 5’-GAGGCTGTTGCTTGTGTGAC-3’. 18s nDNA: forward, 5’-TAGAGGGACAAGTGGCGTTC-3’; reverse, 5’-CGCTGAGGCCAGTCAGTGTA-3’. PCR efficiencies of these primers were tested between 90% and 110%.

4.5. Mitochondria Isolation from Mouse Liver and Cell Lines, Protein Preparation, Blue Native PAGE, and in-Gel Activity Assay

Mitochondria from cultured cell lines were isolated as previously described [41]. Mitochondrial membrane proteins were isolated from mitochondria with n-dodecyl-β-D-maltoside (DDM, Sigma, St. Louis, MO, USA) or digitonin (Sigma). Detergent/protein ratios were 2.5 g/g and 6 g/g for DDM and digitonin, respectively [42]. Protein (60 ug) were separated by BN-PAGE (3%-11% gel) as previously described [42]. For complex I in-gel activity assays, the gels were soaked in assay buffer (25 mg nitrotetrazolium blue (NTB; Sigma) and 10 µL of 1 mg/mL reduced nicotinamide adenine dinucleotide (NADH; Sigma) in 10 mL of 5 mM Tris/HCl (pH 7.4)) for approximately 1 h. For complex IV assays, the gels were soaked in assay buffer (50 mM NaH2PO4 (pH 7.4), 5 mg 3,3’-diamiobenzidine tetra hydrochloride hydrate (DAB), (Sigma) and 50 µM cytochrome c (Sigma)). BN-PAGE with second dimension of Tricine-SDS-PAGE was performed as described elsewhere [42].

4.6. Antibodies and Immunoblotting

Immunoblotting of OXPHOS complexes was conducted as described in [40], and blotting was done with anti-ND1 (1:1000; Abcam, Cambridge, MA, USA), anti-NDUFA13 (Grim19) (1:1000;
MitoSciences, Eugene, OR, USA), anti-SDHA (1:1000; MitoSciences), anti-Core2 (1:1000; MitoSciences),
anti-COX IV (1:11000; MitoSciences), anti-COXI (1:11,000; MitoSciences), anti-ATP synthase subunit
alpha (1:1,100; MitoSciences), anti-β-actin (1:5000; Santa Cruz, Dallas, TX, USA) or anti-VDAC (1:1000;
Cell Signaling, Danvers, MA, USA) antibodies. Integrated optical density (IOD) quantification was
performed using a Gel-Pro Analyzer 4.0 (MediaCybernetics).

4.7. Lactate Measurement

Extracellular lactate level was measured using a fluorimetric based lactate assay kit (Amplite,
Foster City, CA, USA) according to the manufacturer’s instructions. Briefly, culture medium was
filtered through a 10 kDa molecular weight (MW) spin filter (Millipore, Darmstadt, Germany) and
fluorescence was record using a Varioskan™ Flash Multimode Reader (Thermo Scientific, Waltham,
MA, USA).

4.8. ROS Measurement

Mitochondrial ROS were measured according to published protocols [43]. Briefly, cells were
washed in Hank’s buffered salt solution (HBSS), resuspended in HBSS containing 5 µM Mito SOX
(Molecular Probes), and incubated at 37 °C for 15 min. Cells were then washed (twice) with HBSS,
and fluorescence was recorded using a Varioskan Flash Multimode Reader (Thermo Scientific).

4.9. MMP and ATP Measurements

ATP was measured using an ATP measurement kit (Molecular Probes, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Complex I related ATP generation was measured by
treating the cells with 200 nM rotenone for 24 h (Sigma). MMP was determined using the cationic
fluorescent redistribution dye TMRM (Thermo Scientific) as described previously [44].

4.10. Oxygen Consumption

Endogenous oxygen consumption by intact cells was determined using a Clark-type oxygen
electrode (Hansatech, Norfolk, UK) as described previously [20]. After recording the basal respiration,
oligomycin (2.5 µg/mL) (Sigma) was added to measure the un-coupling respiration of the cells.

4.11. Statistical Analysis

The data are presented as the mean ± SD from three independent experiments. Means were
compared using independent Student’s t- tests using SPSS 21.0 software (IBM). p < 0.05 was
considered significant.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/6/
926/s1.

Acknowledgments: This work was supported by grants from the Chinese National Science Foundation
(31370795, 81161120550), Zhejiang Provincial Natural Science Foundation of China (Q15H070017), Key Science
and Technology Innovation Team of Zhejiang Province (2010R50048), and the Start Foundation of Wenzhou Medical
University (to Hezhi Fang).

Author Contributions: Jianxin Lyu and Hezhi Fang planned experiments; Dayan Sun, Bin Li, Ruyi Qiu performed
experiments; Danyan Sun, and Bin Li analyzed data; Jianxin Lyu, Hezhi Fang, and Dayan Sun wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Definition                                |
|--------------|-------------------------------------------|
| BN-PAGE      | blue native polyacrylamide gel electrophoresis |
| ATP          | adenosine triphosphate                    |
| ADP          | adenosine diphosphate                     |
| mtDNA        | mitochondrial DNA                         |
BN-PAGE | blue native polyacrylamide gel electrophoresis  
ATP | adenosine triphosphate  
ADP | adenosine diphosphate  
mtDNA | mitochondrial DNA  
MMP | mitochondrial membrane potential  
ROS | reactive oxygen species  
OXPHOS | oxidative phosphorylation system  
cyt c | cytochrome c  
ETC | electron transfer chain  
NDUFS3 | NADH dehydrogenase (ubiquinone) iron-sulfur protein 3  
CAP | chloramphenicol  
MELAS | mitochondrial encephalopathy, lactic acidosis, and stroke-like episode  
NDUFA13/Grim19 | NADH dehydrogenase (ubiquinone) 1 α subcomplex, 13  
SCAFs | supercomplex assembly factors  
Rcf1/2 | respiratory supercomplex factors 1 and 2  
ND1 | NADH dehydrogenase subunit 1  
DDM | N-dodecyl-β-D-maltoside  
NBT | nitrotetrazolium blue chloride  
DAB | 3,3'-diaminobenzidine tetrahydrochloride hydrate  
BCIP | 5-bromo-4-chloro-3'-indolyphosphate  
p-toluidine |  
TMRM | Tetramethylrhodamine methyl ester

References

1. Wallace, D.C. A mitochondrial bioenergetic etiology of disease. *J. Clin. Investig.* 2013, 123, 1405–1412. [CrossRef] [PubMed]

2. Hackenbrock, C.R.; Chazotte, B.; Gupte, S.S. The random collision model and a critical assessment of diffusion and collision in mitochondrial electron transport. *J. Bioenerg. Biomembr.* 1986, 18, 331–368. [CrossRef] [PubMed]

3. Chance, B.; Williams, G.R. A simple and rapid assay of oxidative phosphorylation. *Nature* 1955, 175, 1120–1121. [CrossRef] [PubMed]

4. Schägger, H.; Pfeiffer, K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. *EMBO J.* 2000, 19, 1777–1783. [CrossRef] [PubMed]

5. Acin-Perez, R.; Fernandez-Silva, P.; Peleato, M.L.; Perez-Martos, A.; Enriquez, J.A. Respiratory active mitochondrial supercomplexes. *Mol. Cell* 2008, 32, 529–539. [CrossRef] [PubMed]

6. Acin-Perez, R.; Enriquez, J.A. The function of the respiratory supercomplexes: The plasticity model. *Biochim. Biophys. Acta* 2014, 1837, 444–450. [CrossRef] [PubMed]

7. Acin-Perez, R.; Bayona-Bafaluy, M.P.; Fernandez-Silva, P.; Moreno-Loshuertos, R.; Perez-Martos, A.; Bruno, C.; Moraes, C.T.; Enriquez, J.A. Respiratory complex III is required to maintain complex I in mammalian mitochondria. *Mol. Cell* 2004, 13, 805–815. [CrossRef]

8. Hornig-Do, H.T.; Tatsuta, T.; Buckermann, A.; Bust, M.; Kolberg, G.; Rotig, A.; Hellmich, M.; Nijtmans, L.; Wiesner, R.J. Nonsense mutations in the COX1 subunit impair the stability of respiratory chain complexes rather than their assembly. *EMBO J.* 2012, 31, 1293–1307. [CrossRef] [PubMed]

9. Li, Y.; D’Aurelio, M.; Deng, J.H.; Park, J.S.; Manfredi, G.; Hu, P.; Lu, J.; Bai, Y. An assembled complex IV maintains the stability and activity of complex I in mammalian mitochondria. *J. Biol. Chem.* 2007, 282, 17557–17562. [CrossRef]

10. Maranzana, E.; Barbero, G.; Falasca, A.I.; Lenaz, G.; Genova, M.L. Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. *Antioxid. Redox Signal.* 2013, 19, 1469–1480. [CrossRef] [PubMed]

11. Blaza, J.N.; Serrelli, R.; Jones, A.J.; Mohammed, K.; Hirst, J. Kinetic evidence against partitioning of the ubiquinone pool and the catalytic relevance of respiratory-chain supercomplexes. *Proc. Natl. Acad. Sci. USA* 2014, 111, 15735–15740. [CrossRef] [PubMed]

12. Schägger, H. Respiratory chain supercomplexes. *IUBMB Life* 2001, 52, 119–128. [CrossRef] [PubMed]

13. Althoff, T.; Mills, D.J.; Popot, J.L.; Kuhlbrandt, W. Arrangement of electron transport chain components in bovine mitochondrial supercomplex IIII2IV1. *EMBO J.* 2011, 30, 4652–4664. [CrossRef] [PubMed]
14. Dudkina, N.V.; Kudryashev, M.; Stahlberg, H.; Boekema, E.J. Interaction of complexes I, III, and IV within the bovine respirasome by single particle cryoelectron tomography. *Proc. Natl. Acad. Sci. USA* 2011, 108, 15196–15200. [CrossRef] [PubMed]

15. Lapuente-Brun, E.; Moreno-Loshuertos, R.; Acin-Perez, R.; Latorre-Pellicer, A.; Colas, C.; Balsa, E.; Perales-Clemente, E.; Quiros, P.M.; Calvo, E.; Rodriguez-Hernandez, M.A.; et al. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. *Science* 2013, 340, 1567–1570. [CrossRef] [PubMed]

16. Mourier, A.; Matic, S.; Ruzzene, B.; Larsson, N.G.; Milenkovic, D. The respiratory chain supercomplex organization is independent of COX7a2l isoforms. *Cell Metab.* 2014, 20, 1069–1075. [CrossRef] [PubMed]

17. Quiros, P.M.; Espanol, Y.; Acin-Perez, R.; Barcena, C.; Watanabe, K.; Calvo, E.; Loureiro, M.; Fernandez-Garcia, M.S.; Fuego, A.; et al. ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. *Cell Rep.* 2014, 8, 542–556. [CrossRef] [PubMed]

18. Rosca, M.G.; Vazquez, E.J.; Kerner, J.; Parland, W.; Chandler, M.P.; Stanley, W.; Sabbah, H.N.; Hoppel, C.L. Cardiac mitochondria in heart failure: Decrease in respirasomes and oxidative phosphorylation. *Cardiovasc. Res.* 2008, 80, 30–39. [CrossRef] [PubMed]

19. Yaffe, D.; Saxel, O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. *Nature* 1977, 270, 725–727. [CrossRef] [PubMed]

20. Bai, Y.; Attardi, G. The mtDNA-encoded ND6 subunit of mitochondrial NADH dehydrogenase is essential for the assembly of the membrane arm and the respiratory function of the enzyme. *EMBO J.* 1998, 17, 4848–4858. [CrossRef] [PubMed]

21. Todaro, G.J.; Green, H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. *J. Cell Biol.* 1963, 17, 299–313. [CrossRef] [PubMed]

22. Ross, S.R.; Choy, L.; Graves, R.A.; Fox, N.; Solejeva, V.; Klaus, S.; Ricquier, D.; Spiegelman, B.M. Hibernoma formation in transgenic mice and isolation of a brown adipocyte cell line expressing the uncoupling protein gene. *Proc. Natl. Acad. Sci. USA* 1992, 89, 7561–7565. [CrossRef] [PubMed]

23. Shinzawa-Itoh, K.; Shimomura, H.; Yanagisawa, S.; Shimada, S.; Takahashi, R.; Oosaki, M.; Ogura, T.; Tsukihara, T. Purification of active respiratory supercomplex from bovine heart mitochondria enables functional studies. *J. Biol. Chem.* 2016, 291, 4178–4184. [CrossRef] [PubMed]

24. Moreno-Lastres, D.; Fontanesi, F.; Garcia-Consuegra, I.; Martin, M.A.; Arenas, J.; Barrientos, A.; Ugalde, C. Mitochondrial complex I plays an essential role in human respirasome assembly. *Cell Metab.* 2012, 15, 324–335. [CrossRef] [PubMed]

25. Kirby, D.M.; McFarland, R.; Ohtake, A.; Dunning, C.; Ryan, M.T.; Wilson, C.; Ketteridge, D.; Turnbull, D.M.; Thorburn, D.R.; Taylor, R.W. Mutations of the mitochondrial ND1 gene as a cause of MELAS. *J. Med. Genet.* 2004, 41, 784–789. [CrossRef] [PubMed]

26. Negishi, Y.; Hattori, A.; Takeshita, E.; Sakai, C.; Ando, N.; Ito, T.; Goto, Y.-I.; Oosaki, M.; Ogura, T.; Tsukihara, T. Purification of active respiratory supercomplex from bovine heart mitochondria enables functional studies. *J. Biol. Chem.* 2016, 291, 4178–4184. [CrossRef] [PubMed]

27. Schägger, H.; Pfeiffer, K. The ratio of oxidative phosphorylation complexes I–V in bovine heart mitochondria and the composition of respiratory chain supercomplexes. *J. Biol. Chem.* 2001, 276, 37861–37867. [PubMed]

28. Spanenberg, L.; Grana, M.; Greif, G.; Suarez-Rivero, J.M.; Krysztal, K.; Tapie, A.; Boidi, M.; Fraga, V.; Lemes, A.; Guecaimburu, R.; et al. 3697G>A in MT-ND1 is a causative mutation in mitochondrial disease. *Mitochondrion* 2016, 28, 54–59. [CrossRef] [PubMed]

29. Valente, L.; Piga, D.; Lamantea, E.; Carrara, F.; Uziel, G.; Cudia, P.; Zani, A.; Farina, L.; Morandi, L.; Mora, M.; et al. Identification of novel mutations in five patients with mitochondrial encephalomyopathy. *Biochim. Biophys. Acta* 2009, 1787, 491–501. [CrossRef] [PubMed]

30. Ikeda, K.; Shibata, S.; Horie-Inoue, K.; Shimokata, K.; Inoue, S. A stabilizing factor for mitochondrial respiratory supercomplex assembly regulates energy metabolism in muscle. *Nat. Commun.* 2013, 4. [CrossRef] [PubMed]

31. Chen, Y.C.; Taylor, E.B.; Dephoure, N.; Heo, J.M.; Tonhato, A.; Papandreou, I.; Nath, N.; Denko, N.C.; Gygi, S.P.; Rutter, J. Identification of a protein mediating respiratory supercomplex stability. *Cell Metab.* 2012, 15, 348–360. [CrossRef] [PubMed]

32. Vukotic, M.; Oeljeklaus, S.; Wiese, S.; Vogtle, F.N.; Meisinger, C.; Meyer, H.E.; Zieseniss, A.; Katschinski, D.M.; Jans, D.C.; Jakobs, S.; et al. Rcf1 mediates cytochrome oxidase assembly and respirasome formation, revealing heterogeneity of the enzyme complex. *Cell Metab.* 2012, 15, 336–347. [CrossRef] [PubMed]
33. Lenaz, G.; Baracca, A.; Barbero, G.; Bergamini, C.; Dal Monte, M.E.; del Sole, M.; Faccioli, M.; Falasca, A.; Fato, R.; Genova, M.L.; et al. Mitochondrial respiratory chain super-complex I-III in physiology and pathology. *Biochim. Biophys. Acta* 2010, 1797, 633–640. [CrossRef] [PubMed]

34. Peters, K.; Dudkina, N.V.; Jansch, L.; Braun, H.-P.; Boekema, E.J. A structural investigation of complex I and I + III2 supercomplex from Zea mays at 11–13 Å resolution: Assignment of the carbonic anhydrase domain and evidence for structural heterogeneity within complex I. *Biochim. Biophys. Acta* 2008, 1777, 84–93. [CrossRef] [PubMed]

35. Schafer, E.; Seelert, H.; Reifschneider, N.H.; Krause, F.; Dencher, N.A.; Vonck, J. Architecture of active mammalian respiratory chain supercomplexes. *J. Biol. Chem.* 2006, 281, 15370–15375. [CrossRef] [PubMed]

36. Heide, H.; Bleier, L.; Steger, M.; Ackermann, J.; Drose, S.; Schwamb, B.; Zornig, M.; Reichert, A.S.; Koch, I.; Wittig, I.; et al. Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly complex. *Cell Metab.* 2012, 16, 538–549. [CrossRef] [PubMed]

37. Chomyn, A.; Lai, S.T.; Shakeley, R.; Bresolin, N.; Scarlato, G.; Attardi, G. Platelet-mediated transformation of mtDNA-less human cells: Analysis of phenotypic variability among clones from normal individuals—And complementation behavior of the tRNAlys mutation causing myoclonic epilepsy and ragged red fibers. *Am. J. Hum. Genet.* 1994, 54, 966–974. [PubMed]

38. Sambrook, J.; Russell, D.W. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: New York, NY, USA, 2001.

39. Rieder, M.J.; Taylor, S.L.; Tobe, V.O.; Nickerson, D.A. Automating the identification of DNA variations using quality-based fluorescence re-sequencing: Analysis of the human mitochondrial genome. *Nucleic Acids Res.* 1998, 26, 967–973. [CrossRef] [PubMed]

40. Fang, H.; Shi, H.; Li, X.; Sun, D.; Li, F.; Li, B.; Ding, Y.; Ma, Y.; Liu, Y.; Zhang, Y.; et al. Exercise intolerance and developmental delay associated with a novel mitochondrial NDS mutation. *Sci. Rep.* 2015, 5, 10480. [CrossRef] [PubMed]

41. Fernandez-Vizarra, E.; Ferrin, G.; Perez-Martos, A.; Fernandez-Silva, P.; Zeviani, M.; Enriquez, J.A. Isolation of mitochondria for biogenetical studies: An update. *Mitochondrion* 2009, 10, 253–262. [CrossRef] [PubMed]

42. Wittig, I.; Braun, H.P.; Schagger, H. Blue native PAGE. *Nat. Protoc.* 2006, 1, 418–428. [CrossRef] [PubMed]

43. Park, J.S.; Sharma, L.K.; Li, H.; Xiang, R.; Holstein, D.; Wu, J.; Lechleiter, J.; Naylor, S.L.; Deng, J.; Lu, J.; et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. *Hum. Mol. Genet.* 2009, 18, 1578–1589. [CrossRef] [PubMed]

44. Sharma, L.K.; Fang, H.; Liu, J.; Vartak, R.; Deng, J.; Bai, Y. Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation. *Hum. Mol. Genet.* 2011, 20, 4605–4616. [CrossRef] [PubMed]

45. Clements, G.B.; Fenyo, E.M.; Klein, G. In vitro derived mouse A9 cell clones differing in malignancy: Analysis by somatic cell hybridization with YACIR lymphoma cell clones. *Proc. Natl. Acad. Sci. USA* 1976, 73, 2004–2007. [CrossRef] [PubMed]

46. Rahbari, R.; Sheahan, T.; Modes, V.; Collier, P.; Macfarlane, C.; Badge, R.M. A novel L1 retrotransposon marker for HeLa cell line identification. *BioTechniques* 2009, 46, 277–284. [PubMed]

47. Luu, H.H.; Kang, Q.; Park, J.K.; Si, W.; Luo, Q.; Jiang, W.; Yin, H.; Montag, A.G.; Simon, M.A.; Peabody, T.D.; et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. *Clin. Exp. Metastasis* 2005, 22, 319–329. [CrossRef] [PubMed]

48. Farina, A.R.; Tacconelli, A.; Cappabianca, L.; Gulino, A.; Mackay, A.R. Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen. *Eur. J. Biochem.* 2002, 269, 4476–4483. [CrossRef]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).